MD Medical Group expands geographical presence with new clinic in Tula
MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, announces that it has opened a new clinic in Tula, approximately 170 km south of Moscow. Investment in the project totalled around 45 million roubles.
Mother&Child Tula has an area of 401 sq m. The clinic offers both the Group’s core services for women such as IVF, ultrasound, minor gynaecological operations in the day-patient centre and OBGYN, as well as medical services for all family members including gastroenterology, endocrinology, neurology, urology and andrology services.
The clinic has annual capacities of up to 400 minor gynaecological operations; up to 1,000 IVF cycles, including under the Mandatory Health Insurance (MHI) programme; and more than 26,000 out-patient treatments per year.
The Tula clinic has been created to MD Medical Group’s customary high standards of medical care and is fitted with world-class equipment produced by Karl Storz, GE, Olympus, and Origio.
Mark Kurtser, CEO of MD Medical Group, said:
“Our first clinic in Tula marks an important step in our strategy of bringing world-class medical care to the Russian regions where our high-tech medical services and new areas of healthcare, such as prenatal diagnosis, next generation sequencing (NGS) preimplantation genetic diagnosis and foetal medicine among others, are not yet well-represented. Tula is an ancient Russian city, and the Tula Region has a population of over 1.5 million.“This clinic will be the 39th medical facility in the Mother&Child network. Like our other clinics and hospitals, it will offer our core OBGYN services and also a number of other services for all members of the family. In addition, it focuses on infertility treatment, including under the MHI programme.”
For further information please contact:
MD Medical Group Investments Plc
Tel: +7 495 331 4120
Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 39 modern healthcare facilities, including 5 hospitals and 34 out-patient clinics in Moscow and the Moscow Region, Tula, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, and Volgograd.
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
2018 2017 2016 2015 2014 2013 2012